Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

NEXT STORY
electroCore to Present at Noble Capital Markets’ Fifteenth Annual Investor Conference
PREV STORY
Sensyne Health and the University of Oxford’s Big Data Institute to establish world-leading research alliance using data science and clinical AI for the patient-centred management and treatment of chronic disease
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy 

author_avatar
NASDAQ Market News

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

author_avatar
NASDAQ Market News

Automated Immunoassay Analysers Market Report Up to 2031: Visiongain Research Inc

author_avatar
NASDAQ Market News